<DOC>
	<DOCNO>NCT00884585</DOCNO>
	<brief_summary>This study evaluate efficacy safety Cyclosporine 0.010 % eye drop treatment Atopic Keratoconjunctivitis ( chronic severe inflammation eye ) . The study consist double-masked phase , open-labeled phase , open-labeled maintenance phase . For first 3 month study , patient receive either mask Cyclosporine 0.010 % eye drop vehicle four time daily ; next 6 month , patient may receive open-labeled Cyclosporine 0.010 % eye drop four time daily . At month 9 , patient remission , re-randomized receive either open-labeled Cyclosporine 0.010 % eye drop four time daily twice daily .</brief_summary>
	<brief_title>Efficacy Safety Study Cyclosporine 0.010 % Treat Atopic Keratoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Have clinical diagnosis Atopic Keratoconjunctivitis ( chronic severe inflammation eye ) Be stable dos current AKC medication least 2 week You use contact lenses within 48 hour Day 1 think may wear contact lens study You pregnant , breastfeeding , plan become pregnant study You use calcineurin inhibitor ( e.g . topical tacrolimus topical pimecrolimus ) around eye include eyelid within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>